150 related articles for article (PubMed ID: 30006927)
1. GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
Chen HJ; Huang RL; Liew PL; Su PH; Chen LY; Weng YC; Chang CC; Wang YC; Chan MW; Lai HC
Int J Cancer; 2018 Dec; 143(12):3106-3119. PubMed ID: 30006927
[TBL] [Abstract][Full Text] [Related]
2. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
4. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
El-Arabey AA; Abdalla M; Abd-Allah AR
Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811
[No Abstract] [Full Text] [Related]
5. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor.
Liu KC; Yo YT; Huang RL; Wang YC; Liao YP; Huang TS; Chao TK; Lin CK; Weng SJ; Ma KH; Chang CC; Yu MH; Lai HC
Oncotarget; 2013 Dec; 4(12):2366-82. PubMed ID: 24280306
[TBL] [Abstract][Full Text] [Related]
7. GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells.
Sakaki H; Okada M; Kuramoto K; Takeda H; Watarai H; Suzuki S; Seino S; Seino M; Ohta T; Nagase S; Kurachi H; Kitanaka C
Anticancer Res; 2015 Dec; 35(12):6607-14. PubMed ID: 26637876
[TBL] [Abstract][Full Text] [Related]
8. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
Fang DD; Cao J; Jani JP; Tsaparikos K; Blasina A; Kornmann J; Lira ME; Wang J; Jirout Z; Bingham J; Zhu Z; Gu Y; Los G; Hostomsky Z; Vanarsdale T
Front Med; 2013 Dec; 7(4):462-76. PubMed ID: 23820871
[TBL] [Abstract][Full Text] [Related]
9. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
[TBL] [Abstract][Full Text] [Related]
10. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
11. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma.
Matsumoto T; Oda Y; Hasegawa Y; Hashimura M; Oguri Y; Inoue H; Yokoi A; Tochimoto M; Nakagawa M; Jiang Z; Saegusa M
Am J Pathol; 2021 Oct; 191(10):1837-1850. PubMed ID: 34214505
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
15. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
16. The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.
Schultz MJ; Holdbrooks AT; Chakraborty A; Grizzle WE; Landen CN; Buchsbaum DJ; Conner MG; Arend RC; Yoon KJ; Klug CA; Bullard DC; Kesterson RA; Oliver PG; O'Connor AK; Yoder BK; Bellis SL
Cancer Res; 2016 Jul; 76(13):3978-88. PubMed ID: 27216178
[TBL] [Abstract][Full Text] [Related]
17. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Létourneau IJ; Quinn MC; Wang LL; Portelance L; Caceres KY; Cyr L; Delvoye N; Meunier L; de Ladurantaye M; Shen Z; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
BMC Cancer; 2012 Aug; 12():379. PubMed ID: 22931248
[TBL] [Abstract][Full Text] [Related]
20. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]